Industrial Consultancy & Sponsored Research (IC&SR) , IIT Madras

Self-labeled Fusion Proteins for Ex Vivo Immunophenotyping of C-kit Receptor

Categories for this Invention

Biotechnology and Genetic Engineering | Drugs and Pharmaceutical Engineering

Industry: Healthcare, Pharma, Biotechnology

Application: Cancer diagnosis and prognosis, Immunophenotyping in leukemia and solid tumor, Allergy and autoimmune disorder diagnostics, Biomarker detection & monitoring, Drug development and personalized medicine

Market: Global Fusion Protein Market size was valued at USD 24.58 Billion in 2023 and is expected to reach USD 32.56 Billion by 2030, at a CAGR of 4.1% from 2023 to 2030.

Image Gallery

Problem Statement

  • Current methods for detecting c-kit expression in cancer, allergies, and autoimmune disorders suffer from inconsistencies due to variations in antibodies and fluorochromes used.
  • Antibody-based detection are complex, costly methods, poses immunogenicity issues.
  • Standardization of c-kit expression detection is challenging due to heterogeneous results from different labs.
  • Hence, there is a need for reliable alternative to antibody-based detection methods for accurate diagnosis and prognosis in cancer and related diseases.

Technology

The technology disclosure introduces a method for detecting expression of c-kit receptor, which is crucial in various diseases including cancer, allergies, and autoimmune disorders.

This antibody-based detection method utilizes self-labeled fusion proteins, consisting of stem cell factor (SCF) fused to SNAP-tag, allowing for covalent binding to detectable agent.

The Process Involves Following Steps:

Genetic Engineering:

  • Fusion constructs of SCF fused to a SNAP tag are cloned into a mammalian vector.

Transfection:

  • The fusion protein probe is transfected into host cells for genetic expression.

Purification:

  • The expressed fusion protein probe is purified from the transfected culture.

Labeling:

  • The probe is labeled with a detectable agent, typically benzylguanine or a derivative thereof with a fluorophore.

Key Features / Value Proposition

  • Simplicity: The production process is simpler compared to antibody production.
  • Cost-effectiveness: It is more cost-effective than antibody-based methods.
  • Specificity: The fusion proteins exhibit high specificity for detecting c-kit expression.
  • Stability: The SCF fused SNAP-tag is stable for extended periods, even at refrigerated temperatures.

Questions about this Technology?

Contact For Licensing

sm-marketing@imail.iitm.ac.in
ipoffice2@iitm.ac.in

Research Lab

Prof. Rama S Verma

Department of  Biotechnology

Intellectual Property

  • IITM IDF No: 1351

  • IN IP No: 415316 (Granted)

Technology Readiness Level

TRL – 4

Technology validated in lab.

error: Content is protected !!